PTO/SB/08s (08-03)
Approved for use through 97/31/2006, 0NE 0851-0331
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE to a collection of information unless it contains a valid OMB control number. Application Number

Filing Date

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)					Named I	nventor	Salv						
					nít		_	I -				_	
					iner Na	me							
					Attorney Docket Num			er AP089-06					
					U.S.I	PATENTS				Remove			
Examiner Initial*	Cite No			Issue [Issue Date		Name of Patentee or Applicant			Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1	4037685	A	1977-0	7-26	Talucci Ar	nthony	,					
	2	4681186	A	1987-0	7-21	Huston Jo	n et a						
If you wish	h to a	dd additional U.S. Pate	nt citatio	n inform	ation pl	ease click	the A	dd button.	_	Add			
			U.S.P	ATENT	APPLIC	CATION P	UBLI	CATIONS		Remove		-	
Examiner Cite Publication Number Kind Code1			Publication Date		Name of Patentee or Applicant of cited Document			Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear					
If you wish	1 h to a	dd additional U.S. Publ	ished Ap	-		n informati	_		d button	Add		_	
				PURE	ON PAI	ENI DOC	UME	MIS	- 1	=			
Examiner Initial*	miner Cite Foreign Document Country No Number ³ Code ² i			Kind Code4	Publication		Name of Patentee or Applicant of cited Document		Pages, Columns, Line where Relevant Passages or Relevan Figures Appear				
	1	9203189	wo		A	1992-03-0	15	Nehaili Ghassan					
	2	19848106	DE		A	1999-05-1	12	Fischer Patrick				П	

	Application Number		
NEODIA TION DIOOL COURT	Filing Date		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	Salva	atore Catania
(Not for submission under 37 CFR 1.99)	Art Unit		
,	Examiner Name		
	A. D. I. I. M. I.		4 D0000 00

If you wish	h to a	id add	ditional Fo	reign Pa	atent E	Docun	ment c	citation	infor	nation	please	click the	Add b	utton	Add			
					NC	ON-P/	ATEN	T LITE	RAT	URE D	OCUM	ENTS			Remo	ve		
Examiner Initials*	Cite No	(bool	ude name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item k, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), isher, city and/or country where published.								Тъ							
	1																	
If you wis	h to a	id add	ditional no	n-patent	t litera	ture c	docum	nent cit	tation	inform	ation pl	ease cli	ck the A	Add b	utton	Add		
							EXA	AMINE	R SIC	NATU	RE							
Examiner	Signa	ture										Date Co	nsiden	ad				
*EXAMIN citation if																	ough a	

16e Knr. Oxee of USPTO Patent Documents at were USPTO_GOV or MPEP 901.64. I Enter office that issued the document, by the Involetor code (WIPO Standard ST.3). "For Implantee patent for Comment, he crickless on the year of the Implant on precede the sent and replant document." I Knr. of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. "Applicant is to place a check mark here if English languages the resistance in a standard."

Application Number Filing Date INFORMATION DISCLOSURE First Named Inventor Salvatore Catania STATEMENT BY APPLICANT Art I Init (Not for submission under 37 CFR 1.99) Examiner Name APRISO, DS Attorney Docket Number

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and	I 1.98 to make the appropriate selection(s):	
----------------------------	--	--

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

- See attached certification statement
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature

Registration Number

Signature	/David A. Guerra/	Date (YYYY-MM-DD)							
Name/Drint	David A Guerra	Registration Number	46443						

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents. P.O. Box 1450. Alexandria. VA 22313-1450

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2504 and 2506. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the state of the s
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.